Kyowa Hakko Kirin To Resume Development Of Kidney Disease Drug Bardoxolone Methyl In Japan
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin will restart its Phase II trials with bardoxolone methyl for the treatment of chronic kidney disease in type 2 diabetes patients, the company announced on July 2.
You may also be interested in...
Outlook For Reata's Bardoxolone Improves With Phase II Updates
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.